Comparative bioequivalence study of Pioglitazone tablets, 20 mg (JSC «Chimpharm», Kazakhstan) and Actos® Tablets, 30 mg («Eli Lilly Holdings, Takeda Global Research and Development Centre Europe Ltd»)

Within the cross, a single, open, randomized study with a two-week washout period, the two sequences has been studied bioequivalence of tablet forms two pioglitazone 18 volunteers (30 mg dosage). Plasma samples were analyzed by a validated HPLC-MS/MS within 48 hours. Analyzed for drugs following pha...

Full description

Saved in:
Bibliographic Details
Main Authors: A. K. Sariev, D. A. Abaimov, M. V. Shiryaev, E. Y. Styrova, S. A. Altynbekov, G. A. Dzholdygulov, V. N. Seryakov, Y. M. Budach, O. E. Kurilo
Format: Article
Language:Russian
Published: LLC “Publisher OKI” 2013-09-01
Series:Фармакокинетика и Фармакодинамика
Subjects:
Online Access:https://www.pharmacokinetica.ru/jour/article/view/132
Tags: Add Tag
No Tags, Be the first to tag this record!